Haemodynamic effects induced by intravenous administration of high doses of r-Met Hu IL-2 [ala-125] in patients with advanced cancer.
作者： D. Diana , J. P. Sculier
DOI: 10.1007/BF01724796
关键词:
摘要: We analyzed the haemodynamic effects of high doses r-Met Hu IL-2 [ala-125] in four patients with advanced cancer. Haemodynamic parameters were measured daily from days 1 to 6 treatment. Mean arterial pressure decreased significantly (98±11 mmHg on day versus 84±7 5;p=0.0435) as did systemic vascular resistance (2042±296 dynes s cm−5 m−2 1166±87 5;p=0.003). There was a significant increase mean pulmonary artery (13.25±3.30 20.75±7.41 5;p=0.03), oxygen consumption (173.5±37.8 ml min−1 257.8±20.5 5;p=0.02) and cardiac index (3.86±0.58 l 5.77±0.21 5;p=0.008). no decrease arteriovenous content difference (4.5±0.8 dl−1 4.46±0.22 5). Increases delivery (570±163 750±109 5 extraction ratio (29.95%±6.37% 34.60%±4.35% 5) not statistically significant. concluded that effect induced by r Hu-IL-2 is similar seen septic shock.
ulb.ac.be
springer.com
sci-hub.se 参考文章(15)
R E Lee, M T Lotze, J M Skibber, E Tucker, R O Bonow, F P Ognibene, J A Carrasquillo, J H Shelhamer, J E Parrillo, S A Rosenberg, Cardiorespiratory effects of immunotherapy with interleukin-2. Journal of Clinical Oncology. ,vol. 7, pp. 7- 20 ,(1989) , 10.1200/JCO.1989.7.1.7
Steven A. Rosenberg, Michael T. Lotze, Linda M. Muul, Susan Leitman, Alfred E. Chang, Stephen E. Ettinghausen, Yvedt L. Matory, John M. Skibber, Eitan Shiloni, John T. Vetto, Claudia A. Seipp, Colleen Simpson, Cheryl M. Reichert, Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic Cancer The New England Journal of Medicine. ,vol. 313, pp. 1485- 1492 ,(1985) , 10.1056/NEJM198512053132327
J.P. Sculier, D. Bron, J. Verboven, J. Klastersky, Multiple organ failure during interleukin-2 administration and LAK cells infusion. Intensive Care Medicine. ,vol. 14, pp. 666- 667 ,(1988) , 10.1007/BF00256776
Hamish R. Michie, Kirk R. Manogue, David R. Spriggs, Arthur Revhaug, Sarah O'Dwyer, Charles A. Dinarello, Anthony Cerami, Sheldon M. Wolff, Douglas W. Wilmore, Detection of circulating tumor necrosis factor after endotoxin administration. The New England Journal of Medicine. ,vol. 318, pp. 1481- 1486 ,(1988) , 10.1056/NEJM198806093182301
R. Nora, J. S. Abrams, N. S. Tait, D. J. Hiponia, H. J. Silverman, Myocardial Toxic Effects During Recombinant Interleukin-2 Therapy Journal of the National Cancer Institute. ,vol. 81, pp. 59- 63 ,(1989) , 10.1093/JNCI/81.1.59
JOSEPH M. KLAUSNER, NICOLE MOREL, IAN S. PATERSON, LESTER KOBZIK, C. R. VALERI, TIMOTHY J. EBERLEIN, DAVID SHEPRO, HERBERT B. HECHTMAN, The rapid induction by interleukin-2 of pulmonary microvascular permeability. Annals of Surgery. ,vol. 209, pp. 119- 128 ,(1989) , 10.1097/00000658-198901000-00017
Jeffrey M. Isner, Cardiovascular Consequences of Recombinant DNA Technology: Interleukin-2 Annals of Internal Medicine. ,vol. 109, pp. 933- 935 ,(1988) , 10.7326/0003-4819-109-12-933
Frederick L. Glauser, Georgean DeBlois, Daniel Bechard, Alpha A. Fowler, Randall Merchant, R. Paul Fairman, Review: Cardiopulmonary Toxicity of Adoptive Immunotherapy The American Journal of the Medical Sciences. ,vol. 296, pp. 406- 412 ,(1988) , 10.1097/00000441-198812000-00007
Ellen R Gaynor, Lauren Vitek, Linda Sticklin, Stephen P Creekmore, Mary E Ferraro, John X Thomas Jr, Susan G Fisher, Richard I Fisher, The Hemodynamic Effects of Treatment with Interleukin-2 and Lymphokine-Activated Killer Cells Annals of Internal Medicine. ,vol. 109, pp. 953- 958 ,(1988) , 10.7326/0003-4819-109-12-953
Steven A Rosenberg, MICHAEL T LOTZE, JAMES J MULÉ, New Approaches to the Immunotherapy of Cancer Using Interleukin-2 Annals of Internal Medicine. ,vol. 108, pp. 853- 864 ,(1988) , 10.7326/0003-4819-108-6-853